


PHARMACEUTICAL 2022

Savara Inc Rank 148 of 466









PHARMACEUTICAL 2022

## Savara Inc Rank 148 of 466



The relative strengths and weaknesses of Savara Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Savara Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 70% points. The greatest weakness of Savara Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 197%, being 119% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	165,000
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,660
Liabilities, Non-Current	17,440
Other Assets	11,525
Other Compr. Net Income	-937
Other Expenses	136
Other Liabilities	0
Other Net Income	-1,537
Other Revenues	0
Property and Equipment	73
Research and Development	28,991
Selling, General and Administrative Expense	12,350

Output Variable	Value in 1000 USD
Assets	176,598
Liabilities	32,100
Expenses	41,477
Revenues	0
Stockholders Equity	144,498
Net Income	-43,014
Comprehensive Net Income	-43,482
Economic Capital Ratio	197%

